Table 2. Reported Adverse Drug Events of Patients (N = 40), by Patient Treatment Completion Status, Study on Using a Collaborative Care Model to Treat LTBI, New Mexico, 2017–2018.
| Type of ADE | No. (%) | Completed Treatmenta (n = 30) |
Discontinued Treatment (n = 10) | P Valuea |
|---|---|---|---|---|
|
No. (%) | ||||
| Any | 24 (60.0) | 15 (50.0) | 9 (90) | .03 |
| Dark urine | 11 (27.5) | 8 (26.7) | 3 (30) | >.99 |
| Nausea/vomiting | 9 (22.5) | 4 (13.3) | 5 (50) | .03 |
| Excessive fatigue | 9 (22.5) | 4 (13.3) | 5 (50) | .03 |
| Appetite loss | 6 (15.0) | 3 (10.0) | 3 (30) | .15 |
| Abdominal discomfort | 6 (15.0) | 3 (10.0) | 3 (30) | .15 |
| Flu-like symptoms | 5 (12.5) | 2 (6.7) | 3 (30) | .09 |
| Urine output change | 3 (7.5) | 1 (3.3) | 2 (20) | .15 |
| Stool color change | 3 (7.5) | 1 (3.3) | 2 (20) | .15 |
| Rash/itching | 2 (5.0) | 0 | 2 (20) | .06 |
| Numbness or tingling | 2 (5.0) | 2 (6.7) | 0 | >.99 |
| Fever >3 days | 1 (2.5) | 1 (3.3) | 0 | >.99 |
| Jaundice | 0 | 0 | 0 | >.99 |
| Bleeding/bruising | 0 | 0 | 0 | >.99 |
| Other | 13 (32.5) | 10 (33.3) | 3 (30) | >.99 |
| Number of ADEs | ||||
| 0 | 16 (40.0) | 15 (50.0) | 1 (10) | .03 |
| 1 | 8 (20.0) | 6 (20.0) | 2 (20) | |
| 2 | 7 (17.5) | 4 (13.3) | 3 (30) | |
| 3 | 1 (2.5) | 1 (3.3) | 0 | |
| 4 | 1 (2.5) | 0 | 1 (10) | |
| 5 | 3 (7.5) | 2 (6.7) | 1 (10) | |
| 6 | 2 (5.0) | 2 (6.7) | 0 | |
| 7 | 2 (5.0) | 0 | 2 (20) | |
Abbreviations: ADE, adverse drug event; LTBI, latent tuberculosis infection.
a
Determined using t test for mean differences and Fisher exact test for frequency differences.